Board of Directors

Dieter Weinand is an experienced executive with over 30 years of experience in the pharmaceuticals and biotech industries. Mr. Weinand presently serves as the Chairman of the Board of Directors of Replimune Group Inc. (NASDAQ: REPL). Previously, Mr. Weinand served as the Executive Vice President of Primary Care and was a member of the Executive Committee at Sanofi from November 2018 to March 2020. Before moving to Sanofi, he was CEO and Chairman of the Board of Management of Bayer Pharma AG and member of the Management Board at Bayer AG. Prior to his work at Sanofi and Bayer, Mr. Weinand held various positions in commercial, operational, and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb, and Otsuka. Mr. Weinand is a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations (EFPIA), and the International Federation of Pharmaceutical Manufacturers (IFPMA), and served as a member of the Board of Directors of HealthPrize Technologies.

Jason Dinges, PhD, JD, is currently an investment advisor at Morningside Technology Advisory LLC, which he joined in 2011.  He has extensive experience providing operational and management oversight to early-stage biotechnology companies.  Dr. Dinges is also a director of several biopharmaceutical or biotechnology companies, across a broad spectrum of therapeutic areas including: Kezar Life Sciences (NASDAQ: KZR), Enyo Pharma, CellCentric, Cognito Therapeutics, Inotrem, ApicBio, Pinteon Therapeutics, and Allysta Pharmaceuticals.  He has also facilitated multiple financings for private companies. From 2006 to 2011, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology, and Pharmaceutical practice group. Dr. Dinges received his Ph.D. in genetics from Iowa State University and a J.D., with highest distinction, from the University of Iowa College of Law.

Kimberly Kelly, PhD founded and has led ZielBio for 5 years. Dr. Kelly is a biomedical engineer specializing in therapeutic target identification. She trained at Hamilton College in Chemistry before receiving her PhD at the Huntsman Cancer Institute at the University of Utah. Kimberly did a postdoctoral fellowship at Massachusetts General Hospital before becoming a Full Professor of Biomedical Engineering at the University of Virginia.  Dr. Kelly serves as reviewer and is on the editorial board of numerous scientific journals, including Molecular Imaging and Biology, Cancer Research, and as the President of the Center for Molecular Imaging Innovation and Translation in SNMMI. A frequent lecturer, she has published over 65 scientific manuscripts and is the inventor of over 20 granted patents and patent applications.

Meredith Fisher, PhD, MBA, is a Partner with Partners Innovation Fund focusing on early stage investments and company creation.  Previously, she was in the private/family office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies. Prior to that role Dr. Fisher led business development for Ginkgo BioWorks – an MIT spin out – and was Senior Director of Technology and Business Development of Enlight Biosciences, a venture creation company founded by PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals. Dr. Fisher received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD from Harvard University. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE). Dr. Fisher is an independent board member at Metera and she also represents PIF on the boards of Nocion and Mediar Therapeutics, and as a board observer at Lyndra and Alizé Pharma.  She is the 2019-2020 co-chair of WEST (Women in the Enterprise of Science and Technology) and serves as an advisor to Takeda HATCH.